As 2018 begins, STAT reporters are taking a look at the stories they’re most eager to track this year. Find all our “three to watch” series here.
Biotechnology is an ever-evolving field, with advances coming at us at a breakneck pace.
And this past year was historic, as it saw some cutting-edge biotech drugs move from the lab to the clinic. The first-ever gene therapy was approved by the Food and Drug Administration to treat a pediatric blood cancer. The CAR-T drug, called Kymriah and marketed by Novartis (NVS), is made by genetically reengineering a patient’s own immune cells to target his or her cancer. Two other gene therapies quickly followed suit: another CAR-T drug from Gilead Sciences (GILD) and a drug from Spark Therapeutics (ONCE) that corrects a rare inherited form of blindness.
What will be the next such breakthroughs? Here, three technologies worth keeping an eye on — because they’re rapidly changing the way that we approach medicine.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect